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Bacterial ghosts are empty cell envelopes produced 
from Gram-negative bacteria controlling E protein 
expression. This control is due to the cloned PhiX174 
lysis E gene. E protein forms a tunnel structure 
spanning the whole cell wall complex, through which 
the cytoplasmic contents are expelled 10-12. 
Recombinant DNA technology facilitates the 
development of multivalent protein or DNA vaccines. 
The expression of recombinant proteins can be 
localized in the outer membrane (OM), the inner 
membrane (IM) and the periplasmic space (PPS) 11. 
 
Figure 2: Zoom in into the bacterial ghost structure. 
We can see the IsdB and SdrD presentation  by the 
E’L’ proteins attached at the IM, and the IsdA 
presentation by the S-layer formation mediated by 
SbsA into the PPS (MalE delivers  S-layer into the PPS). 
On the right side we can see the lysis tunnel 
formation by protein E. 
Recombinant Vibrio cholerae ghost as  a delivery vehicle for 
vaccinating against Staphylococcus aureus 
 
 
The main objective of this project is to create a vaccine able to confer protection against heterologous strains of Stahylococcus aureus. It will induce a cellular immune 
response based on the polarization of CD4T helper cells to Th17 / Th1.  
The initial hypothesis is that the Bacterial Ghost methodology used in the construction of the vaccine is successful, and that the selected antigens (IsdA, IsdB and SdrD) 
generate a specific protective immunity in the individuals who was administered. 
 
Initial hypothesis and objectives 
The vaccine formed by the rVCG expressing IsdA, IsdB and SdrD 
should provide an effective immune response against S.aureus 
and a memory response. The protective response must be 
mediated by Th17 and Th1 cells, increasing the production of IL-
17 and IFN-γ in the vaccinated individuals compared to the 
control ones. This protection will be effective against S.aureus 
due to the use of three different antigens all of them present in 
most of the pathogenic strains. During the lethal challenge, a 
survival increase in immunized mice is expected.  
After the concession of the project 
and its realization, a patent 
application will be submitted. Once 
the patent is granted, the project 
will be disseminated to the scientific 
community through a paper 
publication in a high impact journal 
such as Clinical and Vaccine 
Inmunology (CVI) or Vaccine.  
This project provides a direct solution to one of the major problems in public health 
of the developed world: S.aureus infections are increasing the morbidity and 
mortality every year having an special importance the MRSA strains infections. The 
creation of a feasible vaccine has failed so far because there was a lack of 
information about the immune response able to establish an effective clearance of 
the infection. 
 
To sum up, this vaccine will be cheaper than other approaches because of the 
simple production, it does not depend on complex purification processes, and the 
stock produced can be liophilizated making cold storage unnecessary. 
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Bacterial ghost 
Expected results 
Staphylococcus aureus is a grampositive ubiquitous bacterium from the phylum Firmicutes. It is known to be present as a commensal in the skin and 
nasal microbiome in 25–30% of humans, and it is also a common pathogen, causing  skin and soft tissue infections, such as cellulitis, impetigo, and 
folliculitis1. Although these infections are usually originated in the skin, invasive and life-threatening infections such as bacteremia, pneumonia, 
meningitis, endocarditis, toxic shock syndrome (TSS) and sepsis may ensue 2. During the last decade, the treatment of these infections has been 
difficulted by the irruption of resistant strains, such as methicillin resistant strain (MRSA S.aureus) or vancomicin resistant strain (VRSA S.aureus) 3–5. 
Due to this fact, in United States, S.aureus represents one of the major causes of death. Indeed, it is involved in over 18,000 deceases per year; about 
290,000 hospitalizations and almost 12 million of medical visits and treatments 1. 
 
Different studies established a link between Th17 cells and neutrophils. Interleukin 17A (IL-17A) is known to be important during the neutrophils’ 
recruitment facilitating chemotaxis, eliminating the bacterium easily. Th1 polarization is also required for the neutrophils’ activation at the infection 
side because, for instance, an intracellular stage is known to appear sometimes in S.aureus infections2,9. Finally, it has demonstrated by Stranger 
Jones et al that IsdA, IsdB and SdrD confer protection against S.aureus14 . 
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Figure 1: S.aureus developing a biofilm. 
Soucre: Micronaut 
Chemical synthesis of the genes 
using V.choleare codon usage 
Digestion of pMAL-A 
and IsdA with Ifl III 
Digestion of pKSEL5-2, 
IsdB and SdrD with the 
respective restriction 
enzimes 
Ligation (T4) and 
transformation into 
E.coli JM109 
Selection of clones (LB agar + 
Ampicilllin + Cloramfenicol ). 
 
Confirmation by colony PCR, 
sequencing plasmids. 
Plasmids electroporation in 
V.cholerae H01 
Selection of the clones  
 (BHI +Amp + Cm) 
Electroporation of pDKL01  
Culture growth (BHI + IPTG + 
Antibiotics) until OD 600  of 0.3 
Centrifugation and recombinant 
V.cholerae ghosts (rVCG) 
selection 
Culture BG to confirm 





Lysis  induction  with 3-methilbenzoate 
5 to 8 week old BALB/c mice pathogen free will 
be used. They will be immunized 3 times one 
week in groups of 10: 
Group 1: Intramuscular dose of 3 mg rVCG in 
50 μl of PBS 
Group 2: Im  dose of 1 mg rVCG in 50 μl of PBS 
Group 3: Im dose of 3 mg VCG in 50 μl of PBS 
Group 4: Im dose of 1 mg VCG in 50 μl of PBS 
Group 5: Im dose of 50 μl of PBS in 50 μl of 
PBS 
ELISA to determine antibody titer, IL-17 and 
IFN-γ 
Flow citometry analysis to determinate 
Th17/Th1 cells levels 
Infection of mice with lethal S.aureus dose 
(8.7X108 CFU) and survival study 
Statistical analysis (t student test) 
Obtaining of vaccine subunits Bacterial ghost  formation Protection studies 
Figure 3: Scheme of the genic 
constructs expressing the 
recombinant proteins. 
